Indonesia's National Research and Innovation Agency (BRIN) Partners with MGI to Advance Marine Biodiversity Conservation

Shenzhen, China, 21th December 2023 – MGI, a company committed to building core tools and technology to lead life science, today announced the collaboration partnership with Indonesia's National Research and Innovation Agency (BRIN) on co-building platforms and scientific research innovation. Leveraging advanced platform tools, MGI aims to empower marine genomics research, promoting the conservation and sustainable development of marine biodiversity.

BRIN's Vice chairman , Amarula (right), and MGI's President, Duncan Yu (left)

Indonesia, situated at the confluence of the Pacific and Indian Oceans, is one of the most biodiverse regions globally. The partnership aims to combine their respective strengths, co-build

platforms, and collaborate in utilizing innovative technology to protect and study local genetic resources, contributing to research and conservation efforts for local marine biodiversity in the face of escalating ecological challenges.

Amarula, Vice chairman of Indonesia's National Research and Innovation Agency, highly praised MGI for its breakthroughs in life science tool platform innovation. He welcomes further strengthening of collaboration with MGI in various research areas and platform building in Indonesia.

Duncan Yu, President of MGI, expressed excitement about partnering with BRIN, emphasizing Indonesia's status as one of the richest regions in marine biodiversity. The collaboration will focus on in-depth cooperation in life science tools, technology empowerment, and other areas to assist Indonesia in enhancing research and conservation efforts for biodiversity. 

BRIN's Vice chairman, Amarula (Left), MGI Country Manager Indonesia & Singapore(Right)

Representatives from BRIN and MGI

It is noteworthy that on August 14, 2022, Indonesia officially launched its first "National Genome

Program," with MGI as one of its designated sequencing platform partners. MGI provided a complete set of life science tools, including the DNBSEQ-T7RS high-throughput sequencer, MGISP-960RS high-throughput automated sample preparation system, MGISP-NE384RS fully automated nucleic acid extraction and purification instrument, and the ZTRON integrated data platform. These tools helped establish an efficient, fully automated high-throughput sequencing technology platform, contributing to the program's goal of completing the whole-genome sequencing of 10,000 Indonesians within two years.

In recent years, MGI's platforms and tools have actively supported researchers in various marine genomics research projects, including biological evolution and development, biodiversity and

environmental protection, marine resource exploration, and marine genomics and development, achieving breakthrough results.

As of September 30, 2023, MGI's business spans over 100 countries and regions across six continents, serving a cumulative total of more than 2600 users globally. In the future, MGI will

adhere to a global strategic layout, providing core tools in life sciences with leading technological capabilities to empower global health initiatives and contribute to building a "community of shared future for humanity."

About MGI

MGI Tech Co. Ltd. (or its subsidiaries, together referred to MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers**, and its multi-omics platforms include genetic sequencing**, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.